Swiss Blood Test for colorectal cancer joins race of ‘Liquid Biopsies’

09/05/2016 - 3 minutes

Novigenix has published a validation study of its molecular blood test (Colox) which can reliably detect colorectal cancer at an early stage. Is this the second-place diagnostic in the race for Colorectal cancer blood tests?

novigenix_colorectal_cancer_colox_biomarkerBased in Lausanne (Switzerland), Novigenix is developing molecular diagnostics from a new generation of predictive gene expression profiles and tumor-derived protein markers (biomarkers).

Novigenix first product (Colox) is targeting colorectal cancer. It analyses peripheral blood mononuclear cells (PBMC), and measured the gene expression profile of 29 biomarkers produced by the host immune response to ‘polyps’.

These results are then analysed with proprietary algorithms, which can predict the patients with polyps and early-stage colorectal cancer. This is because polyps can be either benign or malignant, and a test is needed to tell which.

The data from the clinical validation of Colox has now been published in the journal Clinical Cancer Researchwhich has an impact factor of 8.72 (in the top 15 of oncology publications).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member